The activation of T lymphocytes, or T cells, is a crucial process in the immune response, primarily facilitated by antigen presenting cells (APCs) such as dendritic cells. These APCs possess both classes of major histocompatibility complexes (MHCs), specifically MHC class I and MHC class II, allowing them to activate different types of T cells. MHC class I is responsible for activating naive cytotoxic T cells, while MHC class II activates naive helper T cells.
Upon activation, T cells undergo proliferation, creating numerous identical clones that can differentiate into effector T cells or memory T cells. This differentiation is essential for mounting an effective immune response against pathogens. Dendritic cells play a pivotal role in this process by presenting antigens, which can be classified into two major types: harmful (immunogenic) and harmless (non-immunogenic) antigens.
When a dendritic cell presents a harmful antigen, it also expresses co-stimulatory molecules on its surface. These molecules serve as signals that communicate the danger of the antigen to naive T cells, enhancing their activation. In contrast, if a dendritic cell presents a harmless antigen, it does not produce co-stimulatory molecules. Consequently, naive T cells exposed to these harmless antigens do not become activated; instead, they enter a state known as anergy, meaning they become unresponsive. Anergic T cells eventually undergo apoptosis, effectively eliminating the potential for an immune response against harmless antigens.
This mechanism is vital for maintaining immune tolerance, ensuring that the immune system does not react to non-threatening substances, thereby preventing unnecessary immune responses that could lead to tissue damage or autoimmune disorders. Understanding the activation of T lymphocytes and the role of dendritic cells in distinguishing between harmful and harmless antigens is fundamental to immunology and the development of therapeutic strategies for various diseases.